s6y

Quantum Cyber N.V.

Ticker
QUCY
CIK
1874252
Industry
Pharmaceutical Preparations
Formerly
MAINZ BIOMED N.V., Mainz Biomed B.V.

Financials 5

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. NT 20-F Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F for period ending Dec 31, 2021

News 25

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K/A Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 25 news filings

Ownership 40

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4/A Statement of changes in beneficial ownership of securities
  4. 4/A Statement of changes in beneficial ownership of securities
  5. 4/A Statement of changes in beneficial ownership of securities
  6. 4/A Statement of changes in beneficial ownership of securities
  7. 4/A Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 40 ownership filings

Prospectus 26

  1. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  2. S-3 Registration statement for specified transactions by certain issuers
  3. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  4. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  5. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  6. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  7. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  8. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  9. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  10. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

All 26 prospectus filings

Proxies 4

  1. DEF 14A Definitive proxy statements
  2. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  3. DEF 14A Definitive proxy statements
  4. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition

Other 107

  1. SCHEDULE 13G
  2. SCHEDULE 13D/A
  3. EFFECT Notice of Effectiveness
  4. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  5. UPLOAD Letter (PDF)
  6. ARS Annual report to security holders
  7. 144 Filing for proposed sale of securities under Rule 144
  8. 144 Filing for proposed sale of securities under Rule 144
  9. SCHEDULE 13D
  10. SCHEDULE 13G/A

All 107 other filings